The present invention is directed to the use of the peptide compound H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.